Clinical Trial
doi: 10.2165/00126839-200203020-00004.Affiliations
Item in Clipboard
Clinical Trial
Mark A Babizhayev et al. Drugs R D . 2002 .
doi: 10.2165/00126839-200203020-00004.Item in Clipboard
Purpose: To evaluate the effects of 1% N-acetylcarnosine (NAC) solution on lens clarity over 6 and 24 months in patients with cataracts.
Trial design: Randomised, placebo-controlled study.
Participants: 49 subjects (76 affected eyes) with an average age of 65.3 +/- 7.0 years with a diagnosis of senile cataract with minimum to advanced opacification in various lens layers.
Methods: 26 patients (41 eyes) were allocated to topical NAC 1% eyedrops twice daily. The control group consisted of 13 patients (21 eyes) who received placebo eyedrops and 10 patients (14 eyes) who did not receive eyedrops.
Main outcome measures: All patients were evaluated at entry and followed up every 2 months for a 6-month period (trial 1), or at 6-month intervals for a 2-year period (trial 2), for best-corrected visual acuity and glare testing. In addition, cataract was measured using stereocinematographic slit-images and retro-illumination examination of the lens. Digital analysis of lens images displayed light scattering and absorbing centres in two- and three-dimensional scales.
Results: The overall intra-reader reproducibility of cataract measurements (image analysis) was 0.830, and glare testing 0.998. After 6 months, 90% of NAC-treated eyes showed improvement in best corrected visual acuity (7 to 100%) and 88.9% showed a 27 to 100% improvement in glare sensitivity. Topographic studies indicated fewer areas of posterior subcapsular lens opacity and 41.5% of treated eyes had improvement in image analysis characteristics. The overall ratios of image analysis characteristics at 6 months compared with baseline measures were 1.04 and 0.86 for the control and NAC-treated group, respectively (p < 0.001). The apparent benefits of treatment were sustained after 24 months' treatment. No treated eyes demonstrated worsening of vision. The overall visual outcome in the control group showed significant worsening after 24 months in comparison with both baseline and the 6-month follow-up examination. The overall clinical results observed in the NAC-treated group by the 24-month period of examination differed significantly (p < 0.001) from the control group in the eyes with cortical, posterior subcapsular, nuclear or combined lens opacities. Tolerability of NAC eyedrops was good in almost all patients, with no reports of ocular or systemic adverse effects.
Conclusion: Topical NAC shows potential for the treatment and prevention of cataracts.
Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kurysheva NI, Zhukotskii AV, Goldman IM. Babizhayev MA, et al. Peptides. 2001 Jun;22(6):979-94. doi: 10.1016/s0196-9781(01)00407-7. Peptides. 2001. PMID: 11390029 Clinical Trial.
Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J. Babizhayev MA, et al. Drugs R D. 2004;5(3):125-39. doi: 10.2165/00126839-200405030-00001. Drugs R D. 2004. PMID: 15139774 Review.
Prasad K. Prasad K. Mol Cell Biochem. 2019 Sep;459(1-2):95-112. doi: 10.1007/s11010-019-03553-4. Epub 2019 May 11. Mol Cell Biochem. 2019. PMID: 31079281 Review.
Wang L, Liu W, Huang X. Wang L, et al. Libyan J Med. 2018 Dec;13(1):1500347. doi: 10.1080/19932820.2018.1500347. Libyan J Med. 2018. PMID: 30045674 Free PMC article.
Dubois VD, Bastawrous A. Dubois VD, et al. Cochrane Database Syst Rev. 2017 Feb 28;2(2):CD009493. doi: 10.1002/14651858.CD009493.pub2. Cochrane Database Syst Rev. 2017. PMID: 28245346 Free PMC article. Review.
Abdelkader H, Longman M, Alany RG, Pierscionek B. Abdelkader H, et al. Oxid Med Cell Longev. 2016;2016:3240261. doi: 10.1155/2016/3240261. Epub 2016 Oct 16. Oxid Med Cell Longev. 2016. PMID: 27822337 Free PMC article.
Jargin SV. Jargin SV. Oxid Med Cell Longev. 2016;2016:5250386. doi: 10.1155/2016/5250386. Epub 2016 Jul 17. Oxid Med Cell Longev. 2016. PMID: 27500648 Free PMC article. No abstract available.